Global Narcolepsy Drugs Market Report by Disease Type (Daytime Extreme Sleepiness, Cataplexia, Other Disease type) Therapeutic Type (Central Nervous Systems Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Others) End Users (Diagnostics Centers, Hospitals, Others) Countries and Company Analysis, 2024-2032

Growing Knowledge on Narcolepsy Disorders:

The industry is expanding due to the active participation of numerous organizations worldwide in raising awareness of the condition and its symptoms. Additionally, narcolepsy awareness campaigns are growing as a result of growing knowledge about treating sleep problems and narcolepsy.

Furthermore, government initiatives to educate the public and educate professionals about narcolepsy are driving the market's growth, as are growing concerns about the benefits of early detection of the illness.

Consequently, it is anticipated that these variables will propel the market for narcolepsy medications throughout the projected duration. According to the November 2020 study "Narcolepsy Presentation in Diverse Populations: an Update," 0.87 - 1.21 percent of people globally suffer with narcolepsy.

Market players' acceptance and launch of novel medications:

The approval and introduction of new drugs by industry participants is anticipated to be a major factor in driving market growth in the next years. For example, in March 2021, the FDA accepted Avadel's New Drug Application (NDA) for FT218, an experimental once-nightly sodium oxybate composition used to treat narcolepsy patients with excessive levels of sleepiness and cataplexy. 

Global narcolepsy prevalence is expected to continue rising, propelling the industry:

Global narcolepsy prevalence is expected to continue rising, propelling the industry- A paper titled "Prevalence, incidence, and health care utilization of patients with narcolepsy: a population representative study" was published in January 2022. It found that the early prevalence of narcolepsy in Europe ranges from 0.64 to 1.37 cases per 100,000 people.

North America Narcolepsy Drugs Market

The market for narcolepsy medications is dominated by North America, which is expected to rise at a spectacular rate over the course of the projected period. This region is expected to stay dominant because of its high population density, excellent healthcare facilities, and tendency toward population awareness, all of which are expected to drive market expansion. Due to the existence of industry leaders and an excellent healthcare system, the USA has a substantial market share.

Because of increased adoption rates, expanding awareness, and rising disposable income, the United States is also the region with the quickest rate of growth. Because of many governmental agencies that oversee the manufacture of pharmaceuticals, the United States currently controls the majority of the North American market for narcolepsy medications. Regulators such as the US FDA encourage and improve the development of rare disease treatment. The United States and Canada, two North American nations that have supported the use of generic medications, have opened up the markets to an increasing number of foreign competitors. Furthermore, it is anticipated that increased research in the biotechnology and pharmaceutical sectors will support the market's growth throughout the projected decade. The market is expected to rise due to a rise in the number of obese people, a well-developed healthcare sector, and high healthcare costs. The presence of established economies like the United States and Canada, together with other regional firms like Ligand Pharmaceuticals and Mylan N.V., has stimulated the expansion of the narcolepsy medicine industry.

Global Narcolepsy Drugs Company Analysis:

Some leading Narcolepsy Drugs companies are Jazz Pharmaceuticals, Ligand Pharmaceuticals, Novartis AG, Takeda Pharmaceutical, Teva Pharmaceutical, Hikma Pharmaceuticals Plc, Harmony Biosciences Holdings, Roche Holding AG, Johnson & Johnson.

Global Narcolepsy Drugs Company News:

March 2024: More than 1,200 patients have started using Lumryz, a novel narcolepsy medicine intended for once-at-bedtime use, since its launch in June, according to Avadel Pharmaceuticals' fourth-quarter and full-year 2023 update. The business also revealed that over 2,200 patients had enrolled in its RYZUP patient assistance program, the bulk of whom switched from first-generation oxybates. Patients who have never used oxybate medication before as well as those who have experimented with and stopped first-generation oxybate treatment are also enrolled.

January 2024: Jazz Pharmaceuticals, Inc. and UCB (Euronext Brussels: UCB) have signed an enhanced product license agreement for Xyrem® (sodium oxybate). Under the terms of the agreement, UCB will have the exclusive right to market Xyrem® for the treatment of fibromyalgia syndrome, provided that this indication is approved. On September 7th, 2006, Jazz Pharmaceuticals began its Phase III clinical development program for the treatment of fibromyalgia syndrome with Xyrem®.

October 2023: EnsoData and React Health have partnered to support individuals with sleep apnea in adhering to their treatment regimens. EnsoData makes predictions about patients' adherence to therapy using artificial intelligence. React Health manufactures sleep aids. Together, they will integrate EnsoData's predictive AI into React Health's React Health Connect platform. Through this agreement, physicians and equipment providers will have better access to information to support patients who are struggling to follow their treatment regimens.

Key Questions Answered in This Report:

Question:    How big is the Narcolepsy Drugs market?

Answer:     The global Narcolepsy Drugs market size was estimated to reach USD 6,947 million in 2032 while it was estimated to reach US$ 3,471.3 million by 2023.

Question:    What is the Narcolepsy Drugs market growth rate?

Answer:     The global Narcolepsy Drugs market is expected to grow at a compound annual growth rate of 8.01% from 2024 to 2032.

Question:    Who are the key players in Narcolepsy Drugs market?

Answer:     Some key players operating in the Narcolepsy Drugs market includes Jazz Pharmaceuticals, Ligand Pharmaceuticals, Novartis AG, Takeda Pharmaceutical, Teva Pharmaceutical, Hikma Pharmaceuticals Plc, etc.

Question:    What are the factors driving the Narcolepsy Drugs market?

Answer:     Key factors that are driving the Narcolepsy Drugs includes Growing Knowledge on Narcolepsy Disorders, Market players' acceptance and launch of novel medications, Global narcolepsy prevalence is expected to continue rising, propelling the industry, etc.

Question:    Which Region held the largest market share in the Narcolepsy Drugs market?

Answer:     “North America” had the largest share in the Narcolepsy Drugs Market.

Disease Type – Market Breakup in 3 Viewpoints:

1. Daytime Extreme Sleepiness
2. Cataplexia
3. Other Disease type

Therapeutic Type – Market Breakup in 5 Viewpoints:

1. Central Nervous Systems Stimulants
2. Tricyclic Antidepressants
3. Sodium Oxybate
4. Selective Serotonin Reuptake Inhibitor
5. Others

End Users – Market Breakup in 3 Viewpoints:

1. Diagnostics Centers
2. Hospitals
3. Others

Geography – Market Breakup of 17 countries:

North America

1. United States
2. Canada
3. Mexico
4. Brazil

Europe

1. United Kingdom
2. Germany
3. France
4. Italy
5. Spain
6. Netherlands

Asia Pacific

1. China
2. Japan
3. India
4. South Korea
5. Australia

Middle East & Africa

1. South Africa
2. United Arab Emirates

Company Insights:

• Overview
• Business Strategy
• Product Portfolio
• Financial Insight

Key Players Analysis:

1. Jazz Pharmaceuticals
2. Ligand Pharmaceuticals
3. Novartis AG 
4. Takeda Pharmaceutical
5. Teva Pharmaceutical
6. Hikma Pharmaceuticals Plc
7. Harmony Biosciences Holdings
8. Roche Holding AG
9. Johnson & Johnson

Report Details: